单价mRNA疫苗预防3-5岁儿童有症状SARS-CoV-2感染的初步效果估计——增加社区检测机会项目,美国,2022年7月至2023年2月
利用增加社区检测机会(ICATT)项目数据,评估3-5岁儿童接种单价mRNA疫苗对有症状SARS-CoV-2感染的保护效果。完成2剂Moderna后2周至2个月疫苗有效性(VE)为60%(95%CI=49%至68%),3至4个月为36%(95%CI=15%至52%);完成3剂Pfizer-BioNTech后2周至4个月VE为31%(95%CI=7%至49%)。
要点
- 3-5岁儿童完成2剂单价Moderna后2周至2个月,对有症状感染的VE为60%(95%CI=49%至68%)。
- 完成2剂Moderna后3至4个月,VE为36%(95%CI=15%至52%)。
- 3-4岁儿童完成3剂单价Pfizer-BioNTech后2周至4个月,VE为31%(95%CI=7%至49%)。
核心结论
- 完成单价Moderna或Pfizer-BioNTech基础免疫系列分别为3-5岁和3-4岁儿童在接种后至少最初4个月内提供对有症状感染的保护。
- 儿童应继续按推荐接种COVID-19疫苗,包括完成基础免疫系列;符合条件者应接种二价疫苗。
研究设计与样本
- 利用增加社区检测机会(ICATT)项目,在全国药房和社区检测点对≥3岁有COVID-19样症状者进行SARS-CoV-2核酸检测(NAAT)。
- 分析2022年8月1日至2023年2月5日期间3-5岁有症状儿童接种2剂单价Moderna的疫苗有效性。
- 分析2022年9月19日至2023年2月5日期间3-4岁有症状儿童接种3剂单价Pfizer-BioNTech的疫苗有效性。
主要发现
- 3-5岁儿童接种2剂单价Moderna后2周至2个月,对有症状感染的VE为60%(95%CI=49%至68%)。
- 3-5岁儿童接种2剂单价Moderna后3至4个月,对有症状感染的VE为36%(95%CI=15%至52%)。
- 3-4岁儿童接种3剂单价Pfizer-BioNTech后2周至4个月,对有症状感染的VE为31%(95%CI=7%至49%)。
- 统计效力不足以按接种第三剂后时间分层估计VE。
关键数值与推荐
- 2022年6月18日,免疫实践咨询委员会(ACIP)发布临时推荐:2剂单价Moderna COVID-19疫苗作为6个月至5岁儿童的基础免疫系列。
- 2022年6月18日,ACIP发布临时推荐:3剂单价Pfizer-BioNTech COVID-19疫苗作为6个月至4岁儿童的基础免疫系列。
- 2022年12月9日,CDC扩大更新二价疫苗的推荐使用范围至≥6个月儿童。
临床怎么用
- 儿童应继续按推荐接种COVID-19疫苗,包括完成基础免疫系列。
- 符合条件者应接种二价疫苗剂量。
局限性
- 统计效力不足以按接种第三剂后时间分层估计VE。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
On June 18, 2022, the Advisory Committee on Immunization Practices (ACIP) issued interim recommendations for use of the 2-dose monovalent Moderna COVID-19 vaccine as a primary series for children aged 6 months-5 years* and the 3-dose monovalent Pfizer-BioNTech COVID-19 vaccine as a primary series for children aged 6 months-4 years,† based on safety, immunobridging, and limited efficacy data from clinical trials (1-3). Monovalent mRNA vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection was evaluated using the Increasing Community Access to Testing (ICATT) program, which provides SARS-CoV-2 testing to persons aged ≥3 years at pharmacy and community-based testing sites nationwide§ (4,5). Among children aged 3-5 years with one or more COVID-19-like illness symptoms¶ for whom a nucleic acid amplification test (NAAT) was performed during August 1, 2022-February 5, 2023, VE of 2 monovalent Moderna doses (complete primary series) against symptomatic infection was 60% (95% CI = 49% to 68%) 2 weeks-2 months after receipt of the second dose and 36% (95% CI = 15% to 52%) 3-4 months after receipt of the second dose. Among symptomatic children aged 3-4 years with NAATs performed during September 19, 2022-February 5, 2023, VE of 3 monovalent Pfizer-BioNTech doses (complete primary series) against symptomatic infection was 31% (95% CI = 7% to 49%) 2 weeks-4 months after receipt of the third dose; statistical power was not sufficient to estimate VE stratified by time since receipt of the third dose. Complete monovalent Moderna and Pfizer-BioNTech primary series vaccination provides protection for children aged 3-5 and 3-4 years, respectively, against symptomatic infection for at least the first 4 months after vaccination. CDC expanded recommendations for use of updated bivalent vaccines to children aged ≥6 months on December 9, 2022 (6), which might provide increased protection against currently circulating SARS-CoV-2 variants (7,8). Children should stay up to date with recommended COVID-19 vaccines, including completing the primary series; those who are eligible should receive a bivalent vaccine dose.
引用
- Fleming-Dutra KE, Ciesla AA, Roper LE, et al. Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3-5 Years - Increasing Community Access to Testing Program, United States, July 2022-February 2023. MMWR Morb Mortal Wkly Rep. 2023. PMID: 36795625. doi:10.15585/mmwr.mm7207a3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。